NASDAQ:HSCS - Nasdaq - US42254E3027 - Common Stock - Currency: USD
3.3387
-0.06 (-1.8%)
The current stock price of HSCS is 3.3387 USD. In the past month the price increased by 9.87%. In the past year, price decreased by -65.72%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.16 | 225.18B | ||
ISRG | INTUITIVE SURGICAL INC | 63.87 | 174.81B | ||
BSX | BOSTON SCIENTIFIC CORP | 39.41 | 146.31B | ||
SYK | STRYKER CORP | 29.3 | 136.31B | ||
MDT | MEDTRONIC PLC | 15.68 | 107.41B | ||
BDX | BECTON DICKINSON AND CO | 14.54 | 58.09B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.89 | 41.42B | ||
IDXX | IDEXX LABORATORIES INC | 37.92 | 34.57B | ||
RMD | RESMED INC | 24.26 | 31.49B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 14.45 | 29.71B | ||
DXCM | DEXCOM INC | 40.52 | 26.22B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.38 | 22.99B |
HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. The company is headquartered in Southlake, Texas and currently employs 15 full-time employees. The company went IPO on 2022-06-15. The firm has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. The company delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
HEARTSCIENCES INC
550 Reserve St, Suite 360
Southlake TEXAS US
Employees: 15
Company Website: https://heartsciences.com/
Investor Relations: https://ir.heartsciences.com/
Phone: 16822377781
The current stock price of HSCS is 3.3387 USD. The price decreased by -1.8% in the last trading session.
The exchange symbol of HEARTSCIENCES INC is HSCS and it is listed on the Nasdaq exchange.
HSCS stock is listed on the Nasdaq exchange.
8 analysts have analysed HSCS and the average price target is 13.26 USD. This implies a price increase of 297.16% is expected in the next year compared to the current price of 3.3387. Check the HEARTSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HEARTSCIENCES INC (HSCS) has a market capitalization of 3.61M USD. This makes HSCS a Nano Cap stock.
HEARTSCIENCES INC (HSCS) currently has 15 employees.
HEARTSCIENCES INC (HSCS) has a support level at 3.3 and a resistance level at 3.45. Check the full technical report for a detailed analysis of HSCS support and resistance levels.
The Revenue of HEARTSCIENCES INC (HSCS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the HSCS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HSCS does not pay a dividend.
HEARTSCIENCES INC (HSCS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-26.29).
The outstanding short interest for HEARTSCIENCES INC (HSCS) is 3.74% of its float. Check the ownership tab for more information on the HSCS short interest.
ChartMill assigns a technical rating of 2 / 10 to HSCS. When comparing the yearly performance of all stocks, HSCS is a bad performer in the overall market: 84.54% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to HSCS. While HSCS seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months HSCS reported a non-GAAP Earnings per Share(EPS) of -26.29. The EPS increased by 50.4% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -115.8% | ||
ROE | -369.69% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to HSCS. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 80.6% and a revenue growth -100% for HSCS